Table 4.

Comorbidities that developed after anti–PD-1 therapy.

Comorbidity	Melanoma (n = 135)	RCC (n = 44)	NSCLC (n = 38)	Total (n = 217)
Cardiovascular
Atrial fibrillation	2 (1.48%)	1 (2.27%)	0	3 (1.38%)
Carotid stenosis	1 (0.74%)	0	0	1 (0.46%)
Congestive heart failure	3 (2.22%)	2 (4.55%)	0	5 (2.30%)
Coronary artery disease	4 (2.96%)	2 (4.55%)	0	6 (2.76%)
Hyperlipidaemia	3 (2.22%)	1 (2.27%)	0	4 (1.84%)
Hypertension	8 (5.93%)	3 (6.82%)	2 (5.26%)	13 (5.99%)
Peripheral vascular disease	1 (0.74%)	1 (2.27%)	0	2 (0.92%)
Endocrine
Diabetes (type 2)	8 (5.93%)	3 (6.82%)	2 (5.26%)	13 (5.99%)
Adrenal insufficiency	1 (0.74%)	2 (4.55%)	3 (7.89%)	6 (2.76%)
SIADH	0	1 (2.27%)	0	1 (0.46%)
Gastrointestinal
Gastric reflux	10 (7.41%)	5 (11.36%)	6 (15.79%)	21 (9.68%)
Genitourinary
Benign prostatic hyperplasia	3 (2.22%)	3 (6.82%)	0	6 (2.76%)
Erectile dysfunction	3 (2.22%)	0	0	3 (1.38%)
Prostate cancer	1 (0.74%)	0	0	1 (0.46%)
Musculoskeletal
Arthritis	2 (1.48%)	0	0	2 (0.92%)
Osteoporosis	1 (0.74%)	0	0	1 (0.46%)
Neurologic
Dementia	1 (0.74%)	0	0	1 (0.46%)
Migraine	0	1 (2.27%)	0	1 (0.46%)
Seizures	0	1 (2.27%)	0	1 (0.46%)
CVA	0	1 (2.27%)	0	1 (0.46%)
Ocular
Cataracts	2 (1.48%)	1 (2.27%)	0	3 (1.38%)
Corneal dystrophy	1 (0.74%)	0	0	1 (0.46%)
Conjunctivitis	1 (0.74%)	0	0	1 (0.46%)
Pulmonary
COPD/emphysema	0	2 (4.55%)	0	2 (0.92%)
Sleep apnoea	2 (1.48%)	2 (4.55%)	2 (5.26%)	6 (2.76%)
Asthma	1 (0.74%)	2 (4.55%)	0	3 (1.38%)
Psychiatric
Anxiety	5 (3.70%)	2 (4.55%)	3 (7.89%)	10 (4.61%)
Depression	10 (7.41%)	3 (6.82%)	0	13 (5.99%)
Insomnia	1 (0.74%)	1 (2.27%)	0	2 (0.92%)
Renal
Chronic kidney disease	0	3 (6.82%)	0	3 (1.38%)
Renal cell carcinoma	1 (0.74%)	0	0	1 (0.46%)
Other
Breast cancer	0	0	1 (2.63%)	1 (0.46%)
Leukaemia	3 (2.22%)	0	0	3 (1.38%)
Lymphoedema	2 (1.48%)	0	0	2 (0.92%)

anti–PD-1, antibodies to programmed death-1 receptor.